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Abstract
Background: There are limited long-term outcome data in eculizumab-treated patients with atypical hemolytic
uremic syndrome (aHUS). We report final results from the largest prospective, observational, multicenter study of
patients with aHUS treated with eculizumab.
Methods: Patients with aHUS who participated in any of five parent eculizumab trials and received at least one
eculizumab infusion were eligible for enrollment in a long-term follow-up study. Rates of thrombotic microangiopathy
(TMA) manifestations off versus on eculizumab were evaluated. Additional endpoints included change from baseline
estimated glomerular filtration rate (eGFR), long-term renal outcomes, and serious targeted treatment-emergent
adverse events.
Results: Among 93 patients (0–80 years of age), 51 (55%) remained on eculizumab and 42 (45%) discontinued; for
those who discontinued, 21 (50%) reinitiated therapy. Patients who reinitiated eculizumab had similar baseline clinical
characteristics to patients who remained on eculizumab, with higher likelihood of genetic/autoimmune complement
abnormalities, more prior TMAs, and longer disease course versus those who did not reinitiate. Mean eGFR improved
rapidly and remained stable for up to 6 years on eculizumab. In patients who discontinued, there was a trend toward
decreasing renal function over time from discontinuation. Additionally, off-treatment TMA manifestation rates were
higher in those aged < 18 years at diagnosis, with identified genetic/autoimmune complement abnormalities, or
history of multiple TMAs prior to eculizumab initiation. The safety profile was consistent with previous studies. Three
definite and one possible meningococcal infections related to eculizumab were reported and resolved with treatment.
Three deaths unrelated to eculizumab were reported.
Conclusions: The current study confirms the efficacy and safety of eculizumab in aHUS, particularly with regard to
long-term renal function and TMA events. Pediatric age at disease onset and presence of genetic or autoimmune
complement abnormalities are risk factors for TMA events off treatment. Overall, patients who discontinue eculizumab
may be at risk for additional TMA manifestations and renal function decreases. Discontinuation of eculizumab, with
careful monitoring, is an option in select patients with consideration of patient preference, organ function normalization,
and risk factors for relapse, including mutational analysis, age of onset, and history of multiple TMA episodes.
Trial registration: ClinicalTrials.gov NCT01522170, January 31, 2012.
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Background
Atypical hemolytic uremic syndrome (aHUS) is a rare
disorder caused by overactivation of the alternative path-
way of complement and is primarily characterized by
thrombotic microangiopathy (TMA) [1, 2]. Classic mani-
festations include thrombocytopenia, microangiopathic
hemolytic anemia, and acute kidney injury, although
other organs are often also affected. During the era when
plasma infusion or plasma exchange was the mainstay of
management, aHUS was associated with a poor progno-
sis. Historically, 36% of children and 64% of adults de-
veloped end-stage renal disease or died within 3 to 5
years of disease onset [3].
Eculizumab (Soliris®, Alexion Pharmaceuticals, Inc.,
Boston, MA, USA) is a humanized monoclonal comple-
ment inhibitor that is the first and only approved treatment
for patients with aHUS [4, 5]. Eculizumab binds with high
affinity to C5, inhibiting C5 cleavage to C5a and C5b and
preventing the generation of the terminal complement
complex C5b-9, thus inhibiting complement-mediated
TMA. Eculizumab was proven to be effective in patients
with aHUS in five clinical studies [6–10], in which it re-
solved and prevented complement-mediated TMA, im-
proving renal function and hematologic outcomes.
Optimal duration of eculizumab therapy in aHUS has
not yet been determined. The potential risk of develop-
ing TMA following discontinuation of treatment [4, 5]
and the recommendation of lifelong treatment [5] have
been noted in current regulatory guidance. We con-
ducted a large prospective, long-term, observational
study of patients with aHUS who were treated with ecu-
lizumab. Data from an interim analysis (cutoff date:
March 28, 2015; median exposure, 45.9 months) showed
a lower rate of TMA manifestations in patients who
were receiving eculizumab versus patients who were not
on therapy [11]. Here, we report the final results from
this study.
Methods
Study design and patient population
This was a long-term, prospective, observational, multi-
center follow-up study (NCT01522170) of patients with
aHUS who were treated with at least one infusion of
eculizumab in any of five previously conducted parent
studies, several of which included pediatric and/or ado-
lescent patients < 18 years of age [6–10] (Fig. 1).
Study methodology has been published previously
[11], but is summarized in brief herein. Participating pa-
tients received meningococcal vaccination in the parent
eculizumab trials [6, 8, 9] and were revaccinated according
to their respective country guidelines. Use of antibiotic
prophylaxis was not required per the study protocol but
was permitted at the investigators’ discretion. Assessment
of genetic and autoimmune complement abnormalities
was performed in all patients upon entry into the parent
studies by a centralized laboratory and was not repeated
during the current study.
Baseline characteristics were recorded before the first
infusion of eculizumab in the parent studies. In the par-
ent studies, patients were administered eculizumab as
per the dosing schedule described in the prescribing in-
formation. Patients were enrolled in the current study at
the completion of the parent study. During the current
study, changes in dosage and treatment duration were
permitted at the investigators’ discretion. Clinical out-
comes were compared based on eculizumab treatment
status.
The first on-treatment period was defined as the date
from the first infusion through 3 weeks after the last
eculizumab infusion, or until patient discontinuation
from the study or data cutoff (whichever occurred first).
The first off-treatment period was from 3 weeks after
the last infusion of eculizumab until the patient restarted
eculizumab, or until patient discontinuation from the
study or data cutoff (whichever occurred first). Subse-
quent on- and off-treatment periods were defined simi-
larly and patient groups were not mutually exclusive.
Study endpoints and analysis
The primary study endpoint was the rate of TMA mani-
festations in the current study during off and on treat-
ment. The criteria used to define TMA are described in
Table 1 [11]. Additional endpoints included change in
renal function, long-term renal outcomes, and assess-
ment of serious targeted treatment-emergent adverse
events (TEAEs). Post hoc analyses were conducted to
evaluate the TMA manifestation rate by comparing off-
and on-treatment periods in the current study. Rates
were also compared based on patient characteristics, in-
cluding identified genetic or autoimmune complement
abnormalities, age, history of TMA events, and trans-
plant status.
Changes in renal function were measured using esti-
mated glomerular filtration rate (eGFR). For patients who
remained on eculizumab throughout the study, eGFR was
compared between values determined 6months after the
initiation of eculizumab and last follow-up. For patients
who discontinued eculizumab, eGFR was compared imme-
diately prior to discontinuation and at last follow-up. For
patients who discontinued but later reinitiated eculizumab,
eGFR was compared immediately prior to discontinuation
and at last follow-up after eculizumab reinitiation. Patients
were not included in the analysis if these data were unavail-
able. Renal outcomes for individual patients were assessed
independently by the principal investigator and two add-
itional investigators, and reported as improved, stable, or
declined; final findings were adjudicated by the principal
investigator.
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Serious targeted TEAEs were predefined as incidence
of serious infection, meningococcal infection, sepsis,
leukopenia, infusion reactions, hepatic impairment, and
malignancy.
Results
Patient disposition
At the final data cutoff on March 30, 2017, a total of 93
patients (26 children/adolescents, 67 adults) were en-
rolled in the study (Fig. 1). Of these, 82 patients had
on-treatment periods during the current study. Overall,
51 patients (55%; 22 children/adolescents, 29 adults)
remained on eculizumab throughout the current study,
while 42 (45%; 17 children/adolescents, 25 adults) had at
least one off-treatment period. Twenty-one patients
(50%) who discontinued eculizumab later reinitiated
treatment. Reasons for reinitiation included TMA or
renal impairment (n = 11), preparation for a kidney
transplant (n = 5), short discontinuation period due to
change in dose or missed doses (n = 2), administrative
reasons (n = 2), and multiple serious AEs and a change
in dosing (n = 1).
Patient characteristics
Baseline patient characteristics at entry into the parent
studies are presented in Table 2. Overall, 55 patients
(59%) had an identified genetic or autoimmune comple-
ment abnormality. Compared with patients who
Table 1 Definition of TMA manifestation (any one or more
listed criteria) [11]
Type/Severity Criteria
Laboratory values
changea
The occurrence of a change in ≥ 2 laboratory valuesb:
• Platelet count decrease ≥ 25%c and < LLN
• Increase in SCr ≥ 25%c and > ULN
• Increase in LDH ≥ 25%c and > ULN
Clinical signs and
symptoms of TMAd
Clinical signs and symptoms considered
definitely related to aHUS, including:
• Thrombosis
• Seizure
• Reduction in renal function
• Proteinuria (new or worsec and > 1+ or > 30 mg/dL)
• Hematuria (new or worsec and > 50 RBCs/HPF)
• Increased hemolytic anemia
• Biopsy-proven TMA
• Other (eg, extrarenal TMA manifestations, including
confusion, cardiovascular abnormalities, pericarditis,
gastrointestinal symptoms/diarrhea)
Interventiond The patient required PE/PI, dialysis, blood
transfusions, or renal transplant due to a TMA
manifestation
aHUS atypical hemolytic uremic syndrome; HPF high-powered field; LDH
lactate dehydrogenase; LLN lower limit of normal; PE/PI plasma exchange/
plasma infusion; RBCs red blood cells; SCr serum creatinine; TMA thrombotic
microangiopathy; ULN upper limit of normal
aAs determined by changes in laboratory parameters with ongoing follow-up
bMeasurements were required to be confirmed by a second measurement
≥ 28 days apart with no interruption
cDuring each on period, compared with the last laboratory value during the
preceding off period. During each off period, compared with the last value
during the preceding on period
dAs determined at the discretion of the investigator
Fig. 1 Patient disposition
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discontinued eculizumab and did not reinitiate, patients
who reinitiated eculizumab trended toward being youn-
ger (median 21 vs 30 years of age at first eculizumab
dose), male (76% vs 52% female), treated sooner follow-
ing the most recent TMA manifestation (median 0.4 vs
0.6 months), diagnosed for a longer time period before
parent study entry (median 3.0 vs 0.5 months), having
more prior TMA manifestations (38% vs 24% with ≥ 2
manifestations), and being more likely to have genetic or
autoimmune complement abnormalities (67% vs 48%)
(Table 3).
Follow-up and eculizumab exposure
Duration of eculizumab therapy and follow-up time by
treatment status is presented in Additional file 1: Table
S1. The median (range) of follow-up overall (parent and
long-term follow-up studies combined) was 65.7 (9.9,
102.2) months (> 5 years). The duration of eculizumab
treatment prior to the first discontinuation was 19.6
(0.2, 86.9) months and time to reinitiation was 4.7 (0.7,
69.3) months. Patients who reinitiated eculizumab after
discontinuation had an overall exposure of 56.3 (1.3,
91.3) months.
TMA manifestations
During the study, three TMA manifestations occurred in
two patients (2%) during on-treatment periods and 14
TMA manifestations occurred in 10 patients (24%) dur-
ing off-treatment periods (Table 4). The rate of TMA
manifestations was 1.0 per 100 patient-years during
on-treatment periods and 13.5 per 100 patient-years during
Table 2 Demographic and baseline clinical characteristics in the parent studies
Characteristic Never Discontinued
(n = 51)
Discontinued (n = 42) All Patients
(N = 93)Reinitiated
(n = 21)
Not Reinitiated
(n = 21)
Age, at first eculizumab dose, median (range), years 23.0 (0.0, 63.0) 21.0 (0.0, 65.0) 30.0 (0.0, 80.0) 21.0 (0.0, 80.0)
Age < 12 years, n (%) 15 (29) 5 (24) 6 (29) 26 (28)
Female, n (%) 30 (59) 11 (52) 16 (76) 57 (61)
Genetic or autoimmune complement abnormality, n (%)a 31 (61) 14 (67) 10 (48) 55 (59)
No. of TMA manifestations prior to first eculizumab dose, n (%)
1 30 (59) 13 (62) 16 (76) 59 (63)
≥ 2 21 (41) 8 (38) 5 (24) 34 (37)
Time from most recent TMA manifestation to the first eculizumab dose,
median (range), months
1.8 (0.0, 47.4) 0.4 (0.1, 37.8) 0.6 (0.0, 19.2) 0.9 (0.0, 47.4)
Time from aHUS diagnosis to first eculizumab dose, median (range), months 18.0 (0.0, 313.3) 3.0 (0.0, 191.4) 0.5 (0.0, 178.1) 4.0 (0.0, 313.3)
No. of PE/PI sessions at latest TMA manifestation before the first eculizumab
dose, median (range)
13.0 (0.0, 230.0) 7.0 (0.0, 121.0) 7.0 (0.0, 64.0) 10.5 (0.0, 230.0)
Patients with dialysis at baseline of parent study, n (%) 18 (35) 11 (52) 9 (43) 38 (41)
Patients with renal transplant prior to first eculizumab dose, n (%) 14 (28) 4 (19) 5 (24) 23 (25)
aHUS atypical hemolytic uremic syndrome; CFB complement factor B; CFH complement factor H; CFI complement factor I; MCP membrane cofactor protein; PE/PI
plasma exchange/plasma infusion; TMA thrombotic microangiopathy
aIncludes pathogenic variants in C3, CD46 (MCP), CFB, CFH, and CFI, as well as CFH autoantibodies as determined at enrollment in parent studies
Table 3 Genetic and autoimmune complement abnormalities
in patients in the study
Complement
Abnormality by
Risk Level,a n (%)
Never Discontinued
(n = 51)
Discontinued (n = 42)
Reinitiated
(n = 21)
Not Reinitiated
(n = 21)
High risk 25 (49) 8 (38) 6 (29)
CFH 14 (27)b 6 (29) 3 (14)c
C3 6 (12) 1 (5) 1 (5)d
CFH autoantibodies 5 (10) 1 (5) 1 (5)
CFB 0 (0) 0 (0) 1 (5)
Low/moderate risk 6 (12) 6 (29) 3 (14)
CD46 (MCP) 3 (6)e 3 (14) 2 (10)
CFI 3 (6)f 3 (14) 1 (5)
Deletions 0 (0) 0 (0) 1 (5)
CFHR1, CHFR3 0 (0) 0 (0) 1 (5)
No identified
abnormality
20 (39) 7 (33) 11 (52)
CFB complement factor B; CFH complement factor H; CFHR1, CFHR3
complement factor H–related protein 1, complement factor H–related protein
3; CFI complement factor I; MCP membrane cofactor protein
aRisk stratification as proposed by Goodship et al. [17]
bIncludes one patient who also had a CFI mutation, and one patient who also
had a CD46 (MCP) mutation
cIncludes one patient who also had a C3 mutation
dExcludes one patient who also had a CFH mutation
eIncludes one patient who also had a CFI mutation. Excludes one patient who
also had a CFH mutation
fExcludes two patients who also had CFH or CD46 mutations
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Table 4 TMA manifestation rates
Patient Group/Subgroup On-Treatment
Period
Off-Treatment
Period
Fold Change
in Ratea
Percent Decrease on
Versus off Treatment
Overall
Patients n = 82 n = 42
Patients with TMA, n (%) 2 (2) 10 (24)
Manifestations 3 14
Total patient-years 292.5 103.8
Rate per 100 patient-years 1.0 13.5 13.5 93%
Patients who never discontinued
Patients n = 51 N/A
Patients with TMA, n (%) 2 (4) N/A
Manifestations 3 N/A
Total patient-years 218.2 N/A
Rate per 100 patient-years 1.4 N/A N/A N/A
Patients who discontinued eculizumab
Patients n = 31 n = 42
Patients with TMA, n (%) 0 (0) 10 (24)
Manifestations 0 14
Total patient-years 74.2 103.8
Rate per 100 patient-years 0.0 13.5 N/A 100%
Genetic or autoimmune complement abnormality status
Patients with complement abnormality n = 51 n = 24
Patients with TMA, n (%) 1 (2) 7 (29)
Manifestations 2 9
Total patient-years 188.3 50.1
Rate per 100 patient-years 1.1 18.0 16.4 94%
Patients without identified complement abnormality n = 31 n = 18
Patients with TMA, n (%) 1 (3) 3 (17)
Manifestations 1 5
Total patient-years 104.1 53.7
Rate per 100 patient-years 1.0 9.3 9.3 89%
Age at diagnosis
Adult patients n = 41 n = 22
Patients with TMA, n (%) 0 (0) 3 (14)
Manifestations 0 5
Total patient-years 140.5 56.2
Rate per 100 patient-years 0.0 8.9 N/A 100%
Pediatric patientsb n = 41 n = 20
Patients with TMA, n (%) 2 (5) 7 (35)
Manifestations 3 9
Total patient-years 152.0 47.6
Rate per 100 patient-years 2.0 18.9 9.5 89%
History of TMA events
Single TMA n = 51 n = 29
Patients with TMA, n (%) 2 (4) 6 (21)
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off-treatment periods (93% lower on treatment). All 14
TMA manifestations that occurred during off-treatment
periods were reported within the first 30months following
discontinuation. In patients who discontinued eculizumab,
there were no TMA manifestations during on-treatment
periods, and a rate of 13.5 per 100 patient-years in
off-treatment periods.
When stratifying by patient populations (Table 4),
rates of TMA during off- versus on-treatment periods
were particularly high in pediatric onset patients (18.9
per 100 patient-years), patients with identified genetic or
autoimmune complement abnormalities (18.0 per 100
patient-years), and patients with a history of multiple
TMAs (18.0 per 100 patient-years). No TMA manifesta-
tions were reported in patients with transplanted kid-
neys, regardless of treatment status.
Kidney function and long-term renal outcomes
During the first on-treatment period, eculizumab led to
a rapid improvement in mean eGFR, which then
remained above or near ≈60mL/min/1.73 m2 during
follow-up on treatment (Additional file 1: Figure S1A).
In patients who remained on eculizumab treatment
throughout the study and were not on chronic dialysis,
median eGFR was 24.0 mL/min/1.73 m2 at baseline and
59.5 mL/min/1.73 m2 at last follow-up (Table 5). In this
group of patients, dialysis was required by 18 of 51 pa-
tients (35%) at baseline and by 2 (4%) at last follow-up.
Patients who discontinued had a higher mean eGFR at
the time of discontinuation; over time during follow-up
off eculizumab, eGFR slowly decreased but remained >
60mL/min/1.73 m2 (Additional file 1: Figure S1B). In
this patient subgroup, median eGFR was 12.0 mL/min/
1.73 m2 at baseline, 92.3 mL/min/1.73 m2 at time of dis-
continuation, and 75.6 mL/min/1.73 m2 at last follow-up
(median [range] follow-up of 31.2 [0.7, 95.1] months;
Table 5). Of these patients, dialysis was required by 17
of 35 patients (48.6%) at baseline and by 5 of 35 (14.3%)
at last follow-up.
Changes in eGFR over time were analyzed for individ-
ual patients by treatment status to assess long-term
renal outcomes. When comparing long-term kidney
function (Table 6), 37 patients (77%) who remained on
eculizumab treatment had improved or stable renal
function over time; 11 (23%) had a decline in kidney
function. Overall, 14 of 35 patients (40%) who discontin-
ued eculizumab had a decline in renal function, includ-
ing 2 patients (11%) who discontinued and did not
reinitiate eculizumab, and 12 patients (75%) who discon-
tinued eculizumab and reinitiated treatment.
Table 4 TMA manifestation rates (Continued)
Patient Group/Subgroup On-Treatment
Period
Off-Treatment
Period
Fold Change
in Ratea
Percent Decrease on
Versus off Treatment
Manifestations 3 8
Total patient-years 192.7 70.4
Rate per 100 patient-years 1.6 11.4 7.1 86%
Multiple TMA prior to initiation
of eculizumab
n = 31 n = 13
Patients with TMA, n (%) 1 (3) 4 (31)
Manifestations 1 6
Total patient-years 99.8 33.4
Rate per 100 patient-years 1.0 18.0 18.0 94%
Transplant status
Transplanted kidney n = 21 n = 9
Patients with TMA, n (%) 0 (0) 0 (0)
Manifestations 0 0
Total patient-years 76.0 24.3
Rate per 100 patient-years 0.0 0.0 N/A N/A
Native kidney n = 61 n = 33
Patients with TMA, n (%) 2 (3) 10 (30)
Manifestations 3 14
Total patient-years 216.5 79.5
Rate per 100 patient-years 1.4 17.6 12.6 92%
N/A not applicable; TMA thrombotic microangiopathy
aDuring off-treatment periods compared with on-treatment periods. bDefined as age < 18 years at time of diagnosis
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Safety
Overall, eculizumab was well tolerated, and the serious
targeted TEAEs are shown in Additional file 1: Table S2.
Of the reported infections, cases of bacteremia, meningi-
tis, meningococcal infection, pneumococcal infection,
mycoplasma pneumonia, and sepsis were determined to
be related to eculizumab treatment by the investigators.
During the current and parent studies, patients reported
three definite and one possible meningococcal infec-
tions, but all continued eculizumab and recovered from
the infection (Table 7). There were three deaths in the
current and parent studies; none were considered related
to eculizumab (Table 7).
Discussion
We have conducted the largest and longest prospective
cohort study of eculizumab in aHUS patients, across all
age groups. Data from an earlier, interim analysis (cutoff
date: March 28, 2015, median exposure, 45.9 months)
[11] provided preliminary information on rates of TMA
manifestations occurring both off and on eculizumab
treatment. Here, we present the final data from this
study, providing 2 additional years of follow-up, sub-
group analysis that may inform risk profiles, and evalu-
ation of the long-term renal consequences.
In the previous interim analysis [11], TMA manifesta-
tions were defined as either clinical signs and symptoms
of TMA, interventions, or changes in laboratory values.
Although there is no standard definition of TMA, which
may be associated with varying degrees of clinical deteri-
oration and outcomes, it is unlikely that changes in
single laboratory values are considered to be TMA mani-
festations by treating clinicians outside of this trial.
Thus, in this final analysis, we employed the more strin-
gent definition (ie, excluding TMA defined by changes
in a single laboratory criterion) used in the previous in-
terim report [11]. Based on this definition, the rates in
this study were 13.5-fold higher during off-treatment pe-
riods compared with on-treatment periods, consistent
with the interim report.
Ability to identify patients at particular risk for TMA
while off treatment would be beneficial for clinicians when
Table 5 eGFR and dialysis over follow-up by treatment status
Never Discontinued
(n = 51)
Discontinueda
(n = 42)
All Patients
(N = 93)
Patients available for eGFR analysisb, n 39 24 63
eGFR prior to first dose of eculizumab in parent study, mL/min/1.73 m2
Mean (SD) 30.9 (26.9) 29.6 (29.1) 30.4 (27.5)
Median (range) 24.0 (8.4, 128.3) 12.0 (10.0, 105.5) 22.1 (8.4, 128.3)
eGFR at time of discontinuationc, mL/min/1.73 m2
Mean (SD) – 92.4 (38.6) –
Median (range) – 92.3 (34.2, 181.5) –
eGFR at last follow-up, mL/min/1.73 m2
Mean (SD) 65.2 (33.1) 85.9 (31.8) 73.1 (33.9)
Median (range) 59.5 (14.8, 152.2) 75.6 (40.0, 153.5) 65.7 (14.8, 153.5)
Patients on dialysis prior to first dose of eculizumab in parent study, n/N (%) 18/51 (35.3) 17/35 (48.6) 35/86 (40.7)
Patients on dialysis at last follow-up, n/N (%) 2/51 (3.9) 5/35 (14.3) 7/86 (8.1)
eGFR estimated glomerular filtration rate; SD standard deviation
aPatients who had eGFR values recorded in the first off-treatment period; includes patients who did and did not reinitiate eculizumab
bExcludes patients on chronic dialysis, defined as lasting for > 90 days without a gap of > 14 days
cDefined as the last eGFR value before the start of the first off-treatment period in the current study
Table 6 Long-term renal outcomes by treatment status
Patients, n (%) Never
Discontinued
(n = 48)
Discontinued,
Did Not Reinitiate
(n = 19)
Discontinued
and Reinitiated
(n = 16)
All Discontinued
(n = 35)
Improved 17 (35) 2 (11) 0 (0) 2 (6)
Stable 20 (42) 15 (79) 4 (25) 19 (54)
Declined 11 (23) 2 (11) 12 (75) 14 (40)
Note: For patients who never discontinued eculizumab, estimated glomerular filtration rate (eGFR) was compared at 6 months post-eculizumab initiation and at
last follow-up. For patients who discontinued eculizumab, eGFR was compared at the time of discontinuation and at last follow-up. For patients who reinitiated
eculizumab, eGFR prior to discontinuation and at last follow-up (post-reinitiation) was compared. Three patients who remained on eculizumab and seven patients
who discontinued had missing data and were excluded from this analysis. Individual patient outcomes were assessed independently by the principal investigator
and two additional authors. Findings were adjudicated by the principal investigator
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deciding on long-term management, aiming to reduce risk
of TMA relapse. Additional patient enrollment and length
of follow-up allowed for evaluation of TMA manifestation
rates by patient subgroups, although the study was not
specifically designed to facilitate these comparisons. TMA
manifestation rates were particularly high off treatment in
patients with identified complement genetic or auto-
immune abnormalities. These findings are consistent with
previous long-term retrospective analyses of the natural
history of aHUS in the pre-eculizumab era [3, 12] as well
as previous prospective and retrospective analyses of ecu-
lizumab discontinuation [13–16]. Our current findings
also highlight new patient subgroups that may be at par-
ticular risk for TMA relapse when taken off treatment,
including patients with pediatric onset, and/or those with
a history of multiple TMAs. Due to the historically higher
mortality rate in pediatric patients and patients diagnosed
before adulthood, it is crucial to protect these patients
from additional TMA manifestations [3]. When compar-
ing findings from the current analysis to those from a
retrospective study of eculizumab discontinuation in a
French cohort [15], previous history of multiple TMA
manifestations has been consistently identified as a factor
of potential importance for TMA risk while off treatment.
Patients with kidney transplants were excluded from
the analysis by Fakhouri et al. [15], but TMA events
after discontinuation of eculizumab among patients with
aHUS following kidney transplants have been reported
Table 7 Safety events from first dose of eculizumab in parent study
Outcome Sex Age Category Description
Experienced meningococcal infection
while on eculizumab treatment
Female 20–29 • CFH mutation
• Vaccinated with Mencevax® (ACYW135), not on prophylactic
antibiotics
• Meningococcal infection serogroup B identified
• Received antibiotics for treatment of infection, which resolved
after 9 days, and continued on eculizumab
Female 20–29 • CFH mutation, renal transplant
• Vaccinated with Mencevax® (ACYW135), not on prophylactic
antibiotics
• Meningococcal infection serogroup W135 identified
• Received antibiotics for treatment of infection, which resolved
after 17 days, and continued on eculizumab
Male 20–29 • No identified complement abnormality at diagnosis; renal transplant
• Vaccinated with Menveo® (ACYW135), prophylactic antibiotics
• Meningococcal infection serogroup B identified
• Received antibiotics for treatment of infection, which resolved after
10 days, and continued on eculizumab
Male 13–19 • C3 mutation, renal transplant
• Vaccinated with Menactra®, prophylactic antibiotics
• Clinical presentation was consistent with possible meningococcal
infection (sore throat, knee pain and swelling, skin lesions), but all
blood cultures were negative
• Received antibiotics for treatment of infection, which resolved after
6 days, and continued on eculizumab
Deatha Male 30–39 • C3 mutation, renal transplant, hemorrhagic gastric ulcer s/p gastrotomy
• Had discontinued eculizumab approximately 6 months prior to death
• Cause of death: Severe intensive care complications and multiorgan
dysfunction secondary to gastrointestinal hemorrhage, lithiasic cholecystitis,
and sepsis
Male < 5 • No complement abnormality identified at diagnosis;
renal failure, respiratory distress, hepatitis, and seizure disorder
• Patientb experienced abdominal pain, series of infections and bacterial
infection after 10 months on eculizumab at a reduced dose; had seizures
attributed to metabolic encephalopathy
• Cause of death: Hypoxia due to diffuse alveolar hemorrhage
Female < 5 • No complement abnormality identified at diagnosis; renal and cardiac
failure, pulmonary hypertension, cardiomyopathy
• Was on dialysis at diagnosis and was treated with eculizumab for
2 months but discontinued due to “lack of efficacy”
• Patient experienced a TMA manifestation with multiorgan failure
• Cause of death: Respiratory failure led to cardiac arrest and anoxic brain
injury after being off treatment for 7 months
aHUS Atypical hemolytic uremic syndrome, CFH Complement factor H, TMA Thrombotic microangiopathy
aNo death was considered related to eculizumab
bPatient also described in Additional file 1: Table S2
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elsewhere [16]. Interestingly, in this study, no TMA
manifestations were reported off or on treatment in pa-
tients who had transplants. When evaluating profiles of
patients with transplants, patients who remained on
therapy were more likely to have higher-risk comple-
ment abnormalities (ie, CFH, CFB, and C3 mutations)
and/or multiple history of graft loss. This could suggest
that, in this study, transplant patients who discontinued
had a lower risk profile overall. Recent guidance from
Kidney Disease: Improving Global Outcomes (KDIGO)
[17] includes the recommendation that transplant pa-
tients, and particularly those with history of previous
graft loss, should not discontinue eculizumab because of
historically high risk of recurrence and graft loss in the
pre-eculizumab era [18]. Data from a case series by Levi
et al. [19] document risk of TMA post-eculizumab dis-
continuation in a transplant patient. However, Duineveld
et al. [20] suggest that transplantation in aHUS is pos-
sible without prophylactic eculizumab, particularly with
living donors, use of lower-dose immunosuppressive reg-
imens, and strict blood pressure control to mitigate
endothelial injury. Data from the Global aHUS Registry
suggests better outcomes in patients with transplants
who initiated eculizumab prior to transplant [21]. Fur-
ther studies are required for this patient subgroup.
With respect to consequences of TMA and long-term
renal outcomes, this study includes the longest-term
follow-up (median, 65.7 months of follow up [ie, > 5
years]) of changes in eGFR ever reported in patients with
aHUS. Renal function loss following TMA manifestation
was improved with eculizumab, and this improvement
was maintained for a median of 74 months (> 6 years) of
follow-up. At the time of discontinuation, patients who
discontinued eculizumab had higher eGFRs than the
on-treatment plateau value in patients who never dis-
continued. Because discontinuation was at the investiga-
tors’ discretion, we can only speculate as to why this was
the case. It may reflect decreased concern regarding risk
of TMA in patients with fairly normal kidney function,
and a choice was made to discontinue treatment.
We observed a trend toward a decline in kidney func-
tion in the group of patients who discontinued eculizu-
mab. This was observed when evaluating the median
eGFR over time and, more importantly, when evaluating
individual patients during the period when eculizumab
was discontinued. Patients who discontinued eculizumab
were almost twice as likely to have a decline in kidney
function than patients who never discontinued (40% vs
23%) and were less likely to have an improvement in
kidney function (6% vs 35%). Because this decline was ir-
respective of whether a patient had a reported TMA
event, it is possible that some patients had “subclinical”
TMA activity after eculizumab discontinuation. An ana-
lysis of individual patient outcomes in the pediatric
patients in this study (Unpublished data, Pape et al., Euro-
pean Society for Paediatric Nephrology, 2018) revealed
that after eculizumab discontinuation, some patients
maintained renal function but some returned to
pre-eculizumab eGFR values, particularly following a
TMA event. Perhaps not surprisingly, those patients who
reinitiated eculizumab were especially likely to have a de-
cline in kidney function when not receiving eculizumab.
Half of the patients who discontinued eculizumab later
reinitiated during the study, mostly due to TMA/renal
impairment, or in preparation for a kidney transplant.
One patient had multiple serious adverse events and a
change in dosing; treatment was reinitiated to salvage
his condition, but the patient eventually died during this
study. The two patients categorized as “due to change in
dose or missed doses” likely would not have been cate-
gorized as having discontinued in clinical practice, but
were retained in this category based on the definition
in the statistical analysis plan of this study. Shifting
these two patients to the group of patients who
remained on eculizumab based on sensitivity analysis
would not have changed outcomes, because no TMA
manifestations were reported in these patients.
There were differences between the subgroups of patients
who reinitiated eculizumab and those who discontinued
eculizumab and never reinitiated therapy. Interestingly, a
lower proportion of females reinitiated treatment (52% of
the subgroup) than those who never reinitiated treatment
(76% of the subgroup). Patients who reinitiated treatment
were younger and were more likely to have identified com-
plement genetic or autoimmune abnormalities and a his-
tory of multiple TMA manifestations, which is similar to
the subgroup of patients who never discontinued. Evidence
from a pooled, post hoc analysis of the eculizumab clinical
trial program in aHUS [22] demonstrated that younger age
is among the factors associated with better outcomes on
eculizumab. In that analysis, earlier initiation of eculizumab
led to improved renal recovery [22]. It is yet to be deter-
mined how TMA history before initiation of therapy may
affect the disease course after discontinuation.
The safety profile was consistent with those reported
in the parent trials [6–9]. Three deaths were reported
and were determined to be unrelated to eculizumab
treatment. Three definite and one possible meningococ-
cal infections related to eculizumab were reported dur-
ing this study, and resolved with appropriate antibiotic
treatment. The number of meningococcal infections may
be related to the sample size in the study, the severity of
the patient population included in the trial population
[6–9], as well as that the events largely occurred before
the more widespread use of antibiotic prophylaxis. A lar-
ger post-marketing analysis of safety events and, specific-
ally, meningococcal infections has been performed in all
patients treated with eculizumab for paroxysmal nocturnal
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hemoglobinuria and aHUS worldwide. This report pro-
vided 10 years of safety information and included a menin-
gococcal infection rate of 0.25 per 100 patient-years,
which tended to decrease in frequency over that time
period [23]. Clinicians should continue to consult regula-
tory guidance [4, 5] regarding patient counseling of the
eculizumab benefit/risk profile, early signs of meningococ-
cal disease, and processes for seeking immediate medical
care. The Centers for Disease Control and Prevention has
noted that antibiotic prophylaxis is generally considered
to be safe, and suggests that clinicians could consider its
use for the duration of eculizumab treatment [24].
One limitation of this study is that discontinuation of
eculizumab was not done randomly but at the discretion
of investigators and patients, and other possible manage-
ment strategies of aHUS were not evaluated. Hence, the
results must be interpreted cautiously. However, it seems
likely that patients who were perceived to be at higher
risk of TMA would be less likely to discontinue therapy.
Changes in dosage were permitted at the investigators’
discretion and also were not randomized. Another limi-
tation is that small patient numbers and TMA manifes-
tations prevented robust analysis of patient subgroups.
In addition, requirement of serum creatinine level to be
both increased by ≥ 25% and above the upper limit of
normal to qualify as a TMA manifestation may have re-
sulted in missed TMA among patients with low muscle
mass and low baseline creatinine levels. Finally, identifi-
cation and validation of sensitive biomarkers of early
signs of TMA recurrence may assist in managing these
patients long-term for optimal outcomes.
Conclusions
In summary, this long-term, prospective study confirms the
efficacy and safety of eculizumab in the treatment of aHUS,
especially as it relates to improvement and maintenance of
stable kidney function over 6 years and a very low rate of
TMA during that time. Discontinuation of eculizumab was
associated with higher risk of TMA and trends toward de-
creases in renal function over time, despite very high mean
eGFR at the time of discontinuation. These findings confirm
a similar analysis recently conducted in the patient popula-
tion enrolled in the Global aHUS Registry [25]. Patient sub-
groups at the highest potential risk for TMA
post-discontinuation were identified and included pediatric
disease onset, identified genetic or autoimmune complement
abnormalities, and a history of multiple TMAs. Consider-
ation of such risk factors is important during treatment
decision-making for patients with aHUS, and close monitor-
ing for signs of TMA and rapid reinitiation of treatment at
early signs of TMA is needed for patients who discontinue
eculizumab therapy. Under these conditions, discontinuation
of eculizumab with careful monitoring may be an option for
select patients with aHUS.
Additional file
Additional file 1: Table S1. Follow-up by treatment status. Table S2.
Serious targeted TEAEs during current study. Figure S1A and B. Effects
on renal function based on eGFR.
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